JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CRITTENDEN, P. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by CRITTENDEN, P. J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 44, Issue 4, 423-434, 1932
Copyright © 1932 by American Society for Pharmacology and Experimental Therapeutics


STUDIES ON THE PHARMACOLOGY OF METAPHEN AND ACRIFLAVINE

P. JEANETTE CRITTENDEN 1

1 From the Department of Physiology and Pharmacology, Northwestern University Medical School

Metaphen intravenously, except in enormous doses, does not have any effect on the blood pressure, heart rate and respiration of either barbitalized or unanesthetized dogs. In general, intravenous injection of therapeutic doses (0.15 mgm. per kilogram) cause a marked leucocytosis, accompanied by a proportional increase in the different forms of leucocytes. In 1 dog out of ten a leucopenia resulted. It has no effect in similar doses on the fragility of erythrocytes. The minimum lethal dose of metaphen in dogs is 3.5 mgm. per kilogram, which on the basis of its mercury content is equivalent to the minimum lethal dose of bichloride of mercury.

Certain preparations of acriflavine are definitely toxic, causing marked changes in the heart rate, circulation, and respiration, and nausea and vomiting in intravenous doses of from 2 to 5 mgm. per kilogram. A neutral preparation of acriflavine can be prepared which in doses of from 1 to 2 mgm. per kilogram causes either no or only slight changes in heart rate, respiration and blood pressure. Preparatinns of acriflavine should be tested on unanesthetized animals before they are used for intravenous therapy. Even the least toxic preparations of acriflavine in small doses stimulate and in larger doses depress the peripheral vagal mechanism in the heart. Our results indicate that the chief point of action of acriflavine on the blood pressure is pheripheral.

Submitted on October 2, 1931







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1932 by the American Society for Pharmacology and Experimental Therapeutics.